Last reviewed: August 2026. Based on ESUR 2025, the European Thyroid Association recommendations and ACR 2024. This page is revised and re-dated when the guidance changes.
Iodinated contrast media interact with the thyroid more than with most other organ systems, and in 2025 the rules changed. ESUR has dropped the universal recommendation for TSH screening before CT, but a defined set of patients still need structured assessment: Suppressed TSH, planned radioiodine therapy, amiodarone, post-thyroidectomy status, and a few less obvious laboratory constellations.
The tool below walks through the same logic I use in the Gantry app (built on ESUR 2025, ETA, and ACR 2024) and produces a green / yellow / red recommendation in under a minute, including specific guidance on sodium perchlorate, nuclear medicine referral, and when to defer the scan. It is intended for radiologists, referring physicians, and trainees. It does not replace clinical judgement.
When is TSH screening required before iodinated contrast?
ESUR 2025 removed the universal TSH-screening recommendation that many institutions still treat as default. In my reading of the current guidance, TSH is only required in patients with a defined risk profile:
- Known nodular goitre, autonomous adenoma, or focal/diffuse thyroid autonomy. These patients carry the highest risk of iodine-induced hyperthyroidism after contrast exposure.
- A history of hyper- or hypothyroidism, even if currently treated. Amiodarone is a separate category that needs specialist co-assessment.
- Clinical signs of thyroid dysfunction: tachycardia, tremor, heat intolerance, weight loss without effort, or the opposite spectrum.
If none of these apply, no TSH is needed before iodinated contrast. If a TSH value already exists and is ≤ 3 months old, that result is acceptable; you do not need to repeat the test. The 3-month rule reflects the typical stability of thyroid function, not the analyte itself, and is consistent with current ETA practice.
However (yes, there is always a “however”), things change slowly and we like to be cautious. Therefore, there are a lot of institutions that for example use age (e.g., >50/60/65 years) as a general rule on when TSH is necessary before administration of iodinated contrast.
A normal TSH in a low-risk patient effectively rules out the most relevant complication of iodinated contrast administration, regardless of free hormone levels. That single line is what I tell most of the referring physicians who call.
Risk groups in detail
Nodular goitre and thyroid autonomy
Patients with multinodular goitre or known autonomous adenoma have the highest iodine-induced hyperthyroidism risk after contrast exposure (the Jod-Basedow phenomenon). The risk is proportional to the volume of autonomous tissue and the iodine load delivered. For these patients, a current TSH is mandatory. If TSH is normal, the contrast study can usually proceed; follow-up TSH at 4 to 6 weeks is a reasonable safety net. If TSH is suppressed, endocrinology or nuclear medicine consultation is required before proceeding.
Manifest versus latent hyperthyroidism
Manifest hyperthyroidism (TSH < 0.1 with elevated fT3 or fT4) is the one absolute contraindication. Everything else is a precaution. The tool flags this constellation as red.
Latent (subclinical) hyperthyroidism, meaning suppressed TSH with normal free hormones, is yellow rather than red. The risk of conversion to manifest hyperthyroidism after iodine exposure is real but not absolute. Nuclear medicine work-up (scintigraphy) followed by short-course sodium perchlorate is the standard approach if CT cannot be deferred.
A common pitfall: A critically ill patient with suppressed TSH and normal free hormones may have sick euthyroid syndrome rather than true autonomy. Differentiation needs endocrinology input. Sick euthyroid is mostly not a contraindication to contrast.
Patients on L-thyroxine and a suppressed TSH
L-thyroxine substitution at doses > 50 µg/day frequently suppresses TSH while leaving free hormones in the normal range. This is not autonomy and (in most cases) not a contraindication. Sodium perchlorate is not required. The tool returns green here, because the thyroid tissue under exogenous L-thyroxine suppression has very limited autonomous potential. The substituted hormone is doing the work, not the gland itself.
An exception is intentional TSH suppression after thyroidectomy for thyroid carcinoma. No autonomous tissue remains. Suppressed TSH is therapeutic, contrast is unrestricted, and sodium perchlorate is unnecessary.
What I see most often on shift: A suppressed TSH that turns out to be L-thyroxine substitution, flagged as a contraindication by an automated system (or younger residents). It almost never is.
Amiodarone
Amiodarone contains roughly 37% iodine by weight. Even a single 200 mg tablet delivers iodine orders of magnitude above daily intake. The drug also inhibits T4 to T3 conversion, producing a characteristic laboratory pattern: fT4 elevated, fT3 low or low-normal, TSH variable. Interpreting thyroid status in amiodarone patients without specialist input is unreliable. I would not administer contrast to an amiodarone patient with suppressed TSH without an endocrinology or nuclear medicine opinion.
Biotin interference with TSH immunoassay
High-dose biotin (> 1 mg/day) can falsely suppress TSH on most immunoassays. Patients on biotin for hair, nail or multiple sclerosis indications occasionally present with apparently suppressed TSH and normal free hormones. The constellation is indistinguishable from latent hyperthyroidism until the biotin is discontinued and the TSH retested 48 hours later. Ask. Document. If in doubt, repeat the TSH off biotin.
When iodinated contrast is contraindicated
Iodinated contrast media are contraindicated in:
- Manifest hyperthyroidism. TSH suppressed with elevated fT3 or fT4. Defer the study and consult endocrinology. If the indication is vital and the study cannot be deferred, sodium perchlorate 40 drops plus thiamazole 40 mg IV before contrast administration, then 3 × 20 drops sodium perchlorate per day for 14 days, with thyrostatic dosing managed by endocrinology/nuclear medicine.
- Planned radioiodine therapy. Iodinated contrast saturates the sodium-iodide symporter and blocks radioiodine uptake into thyroid tissue. The washout intervals are 3 to 4 weeks for hyperthyroidism and 6 weeks for differentiated thyroid carcinoma. If CT is urgently needed, I would defer the radioiodine therapy rather than the CT.
Lactation and pregnancy are handled in separate modules of the Gantry app and are not covered by this tool. In brief: Iodinated contrast in pregnancy is justified if clinically indicated, with neonatal TSH screening in the first week of life. Lactation is uniformly safe and does not require interruption.
Sodium perchlorate premedication
Sodium perchlorate (brand name “Irenat”, sodium perchlorate generically) competitively inhibits iodide uptake at the sodium-iodide symporter, blunting the iodine load delivered by contrast media. It is the workhorse drug for thyroid prophylaxis around iodinated contrast.
Standard regimens I use:
- Latent hyperthyroidism / suspected autonomy, CM urgent: 40 drops before CM, then 3 × 20 drops/day for 7 days.
- Vital indication in manifest hyperthyroidism: 40 drops + thiamazole 40 mg IV before CM, 20 drops again in the evening, then 3 × 20 drops/day for 14 days, with thyrostatic management by endocrinology. Please dont just copy that: Read the SOP and guidelines at your institution – everyone should have something documented, where you can rely on.
- Precautionary in fT4 elevated under L-thyroxine > 50 µg/day: 40 drops as a single dose.
Sodium perchlorate is the workhorse for yellow-flag constellations, not routine prophylaxis for unselected patients.
When perchlorate is not needed:
- Normal TSH with normal free hormones. No precaution required.
- Suppressed TSH explained by L-thyroxine substitution > 50 µg/day with normal free hormones. No autonomous potential.
- Post-thyroidectomy status, even with suppressed TSH. No thyroid tissue to protect.
Standard follow-up after perchlorate: TSH and free hormones at 1 week (if started for autonomy) or 4 to 6 weeks (in stable latent constellations).
Post-thyroidectomy and post-radioiodine patients
After total thyroidectomy with no clinical evidence of recurrence or residual functioning tissue, no autonomous thyroid tissue remains. Iodinated contrast is unrestricted. Sodium perchlorate is not required. Subtotal or hemi-thyroidectomy patients are screened like any patient with residual thyroid tissue and should not use this branch.“
Patients on TSH-suppressive levothyroxine therapy after thyroidectomy for differentiated thyroid carcinoma frequently present with TSH below 0.1. This is therapeutic, not pathological. Do not confuse it with latent hyperthyroidism. The tool handles this branch automatically when the post-thyroidectomy path is chosen.
Lactation, pregnancy, paediatrics
These groups are not covered by this tool because the decision tree is materially different. Briefly:
- Pregnancy: Iodinated contrast is permissible if the maternal indication is sufficient. Neonatal TSH is screened in the first week.
- Lactation: Continue breastfeeding without interruption. The small amount of iodinated contrast secreted into breast milk is clinically irrelevant.
- Paediatrics: Dosing is weight-based (1.5 to 2 ml/kg). Neonates under three weeks have unreliable creatinine due to maternal residual, and renal screening is interpreted accordingly.
The Gantry app contains dedicated modules for each of these. See the download links at the end of this page.
Frequently asked questions
Do all patients need TSH measurement before CT contrast?
No. ESUR 2025 removed the universal screening recommendation. TSH is only needed in patients with nodular goitre, known thyroid autonomy, prior hyper- or hypothyroidism, or clinical signs of thyroid dysfunction. Existing TSH up to three months old is acceptable.
What TSH value is too low for iodinated contrast?
TSH below 0.1 mU/L with elevated free T3 or T4 indicates manifest hyperthyroidism (absolute thresholds may vary by laboratory though!). Iodinated contrast is contraindicated except for vital indications. Suppressed TSH on L-thyroxine substitution over 50 µg/day with normal free hormones is usually a treatment effect and not a contraindication.
Can a patient on amiodarone receive iodinated contrast?
Yes, but only after endocrinology or nuclear medicine consultation. Amiodarone itself contains around 37% iodine and produces an atypical thyroid hormone pattern (fT4 elevated, fT3 low). Suppressed TSH in this context warrants specialist input before contrast.
How long should I wait between iodinated contrast and radioiodine therapy?
Three to four weeks for hyperthyroidism, six weeks for differentiated thyroid carcinoma. Iodinated contrast saturates the sodium-iodide symporter, which blocks radioiodine uptake into thyroid tissue. If the CT is urgent, defer the radioiodine therapy rather than the CT.
Is iodine allergy a contraindication for iodinated contrast media?
It depends on what the patient actually reacted to, and the two cases are very different.
A prior hypersensitivity reaction to an iodinated contrast medium is a real and relevant risk factor. It is the single best predictor of a repeat reaction. Mild prior reactions (urticaria, transient flush) can usually be managed with a different contrast agent and, if elective, premedication discussed with allergology. Moderate to severe reactions warrant allergology workup, premedication and maybe even skin testing before re-exposure, and severe / anaphylactic reactions are a hard contraindication outside vital indications.
A reported “iodine allergy” in the colloquial sense is not a real entity. Elemental iodine is not allergenic. What patients usually mean by it is one of three things: shellfish allergy (the allergen is tropomyosin, not iodine), povidone-iodine skin reaction (directed at the carrier, not iodine), or a historical contrast reaction without a clear record. None of the first two predicts an iodinated contrast reaction. Only a documented prior contrast hypersensitivity matters.
Does L-thyroxine substitution mean iodinated contrast is unsafe?
No. L-thyroxine substitution at doses over 50 µg/day frequently suppresses TSH while leaving free hormones normal. Under these conditions, autonomous thyroid potential is minimal and contrast is administered without sodium perchlorate. The tool above handles this branch automatically.
Should I premedicate with sodium perchlorate before every CT?
No. Sodium perchlorate is indicated in defined yellow-flag constellations: latent hyperthyroidism with autonomy, atypical laboratory patterns suggestive of T4 autonomy, or suspected nodular goitre when CT cannot be deferred. It is not routine prophylaxis for unselected patients with normal TSH.
What about post-thyroidectomy patients with suppressed TSH?
After total thyroidectomy, no autonomous tissue remains. Suppressed TSH in these patients is typically intentional (TSH-suppressive therapy for thyroid carcinoma) and not a contraindication. Iodinated contrast is unrestricted and no perchlorate is required. However, if you think that there might not have been a TOTAL thyroidectomy and some tissue is left or recurrant, the patient should be treated as if its “normal” tissue with caution.
How to cite this tool
If this decision aid informed a protocol, a teaching session or a manuscript, a citation is welcome and helps others find it. Text and BibTeX below.
Decker JA. Iodinated Contrast and the Thyroid: A Decision Tool for CT. Rad Insights, 2026. https://rad-insights.com/thyroid-contrast-check/
@misc{decker_thyroid_contrast,
author = {Decker, Josua A.},
title = {Iodinated Contrast and the Thyroid: A Decision Tool for CT},
year = {2026},
howpublished = {\url{https://rad-insights.com/thyroid-contrast-check/}}
}
The tool is free to use and free to link. If you would like it embedded in a departmental intranet or a teaching resource, the contact address is on the contact page.
References and further reading
- ESUR Guidelines on Contrast Media v10.0 (2025)
- ACR Manual on Contrast Media 2024/2025
- ETA 2021 guideline on management of patients exposed to iodinated contrast media. European Thyroid Association.
- Interactive multilingual version of the ESUR guidelines
About
Feedback is welcome. If you spot a guideline mismatch, an institutional protocol that contradicts the recommendation, or simply unclear wording: there is a feedback button inside the tool, or you can email me directly. I am happy to revise.
Conflict of interest: I built the Gantry app referenced above. The web tool on this page is free and contains the same content as the app’s thyroid module.
This page is a decision aid and does not replace individual clinical judgement, institutional protocols, or endocrinology consultation. Final responsibility for the contrast decision rests with the treating physician.
Offline access to 50+ guided RADS flows, calculators (eGFR, MESA, GBCA, washout, Brock), and the full ESUR/ETA contrast-media decision logic. By Josh Decker, MD.
A related question that gets asked less often than it should: whether contrast volumes are being handed out evenly. There is a short piece here on potential gender bias in contrast dosing, and whether women are receiving more than their body mass justifies.
